English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

According to World Health Organization (WHO) reports, chronic obstructive pulmonary disease (COPD) is the third-leading cause of deaths worldwide.[1] Further, it is the sixth-leading cause of disabilityadjusted life years (DALYs) in middle-income countries – a figure that is expected to change to the fifth-leading cause worldwide in 2030 – and the significance of the disease is becoming quite evident. In response to this, AstraZeneca, a global, research-based biopharmaceutical company with a vested interest in the development of life-changing respiratory medications, has launched a cross-sectional study of patients with severe COPD that assesses patient perception of symptom variability in Middle East and African (MEA) countries.

AstraZeneca Pharmaceuticals responds to the chronic obstructive pulmonary disease crisis with the launch of a non-interventional study – COPVAR